Literature DB >> 23022070

Lysine restricted diet for pyridoxine-dependent epilepsy: first evidence and future trials.

Clara D M van Karnebeek1, Hans Hartmann, Sravan Jaggumantri, Levinus A Bok, Barb Cheng, Mary Connolly, Curtis R Coughlin, Anibh M Das, Sidney M Gospe, Cornelis Jakobs, Johanna H van der Lee, Saadet Mercimek-Mahmutoglu, Uta Meyer, Eduard Struys, Graham Sinclair, Johan Van Hove, Jean-Paul Collet, Barbara R Plecko, Sylvia Stockler.   

Abstract

OBJECTIVE: To evaluate the efficacy and safety of dietary lysine restriction as an adjunct to pyridoxine therapy on biochemical parameters, seizure control, and developmental/cognitive outcomes in children with pyridoxine-dependent epilepsy (PDE) caused by antiquitin (ATQ) deficiency.
METHODS: In this observational study, seven children with confirmed ATQ deficiency were started on dietary lysine restriction with regular nutritional monitoring. Biochemical outcomes were evaluated using pipecolic acid and α-aminoadipic semialdehyde (AASA) levels in body fluids; developmental/cognitive outcomes were evaluated using age-appropriate tests and parental observations.
RESULTS: Lysine restriction was well tolerated with good compliance; no adverse events were reported. Reduction in biomarker levels (measurement of the last value before and first value after initiation of dietary lysine restriction) ranged from 20 to 67% for plasma pipecolic acid, 13 to 72% for urinary AASA, 45% for plasma AASA and 42% for plasma P6C. For the 1 patient in whom data were available and who showed clinical deterioration upon interruption of diet, cerebrospinal fluid levels decreased by 87.2% for pipecolic acid and 81.7% for AASA. Improvement in age-appropriate skills was observed in 4 out of 5 patients showing pre-diet delays, and seizure control was maintained or improved in 6 out 7 children.
CONCLUSIONS: This observational study provides Level 4 evidence that lysine restriction is well tolerated with significant decrease of potentially neurotoxic biomarkers in different body compartments, and with the potential to improve developmental outcomes in children with PDE caused by ATQ deficiency. To generate a strong level of evidence before this potentially burdensome dietary therapy becomes the mainstay treatment, we have established: an international PDE consortium to conduct future studies with an all-inclusive integrated study design; a website containing up-to-date information on PDE; a methodological toolbox; and an online registry to facilitate the participation of interested physicians, scientists, and families in PDE research.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23022070     DOI: 10.1016/j.ymgme.2012.09.006

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  23 in total

1.  Glial localization of antiquitin: implications for pyridoxine-dependent epilepsy.

Authors:  Laura A Jansen; Robert F Hevner; William H Roden; Si Houn Hahn; Sunhee Jung; Sidney M Gospe
Journal:  Ann Neurol       Date:  2014-01-02       Impact factor: 10.422

2.  Long-Term Follow-up of a Successfully Treated Case of Congenital Pyridoxine-Dependent Epilepsy.

Authors:  Malcolm Proudfoot; Philip Jardine; Agne Straukiene; Rupert Noad; Andrew Parrish; Sian Ellard; Stuart Weatherby
Journal:  JIMD Rep       Date:  2013-02-12

3.  Early identification of treatable inborn errors of metabolism in children with intellectual disability: The Treatable Intellectual Disability Endeavor protocol in British Columbia.

Authors:  Clara Dm van Karnebeek; Sylvia Stockler-Ipsiroglu
Journal:  Paediatr Child Health       Date:  2014-11       Impact factor: 2.253

4.  Current treatment and management of pyridoxine-dependent epilepsy.

Authors:  Clara D M van Karnebeek; Sravan Jaggumantri
Journal:  Curr Treat Options Neurol       Date:  2015-02       Impact factor: 3.598

5.  Phenotype, biochemical features, genotype and treatment outcome of pyridoxine-dependent epilepsy.

Authors:  Amal Al Teneiji; Theodora U J Bruun; Dawn Cordeiro; Jaina Patel; Michal Inbar-Feigenberg; Shelly Weiss; Eduard Struys; Saadet Mercimek-Mahmutoglu
Journal:  Metab Brain Dis       Date:  2016-11-23       Impact factor: 3.584

6.  Pyridoxine-dependent epilepsy (PDE-ALDH7A1) in adulthood: A Dutch pilot study exploring clinical and patient-reported outcomes.

Authors:  L A Tseng; L Teela; M C Janssen; L A Bok; M A A P Willemsen; R F Neuteboom; L Haverman; S M Gospe; C R Coughlin; C D M van Karnebeek
Journal:  Mol Genet Metab Rep       Date:  2022-03-04

7.  Untargeted metabolomics and infrared ion spectroscopy identify biomarkers for pyridoxine-dependent epilepsy.

Authors:  Udo Fh Engelke; Rianne E van Outersterp; Jona Merx; Fred Amg van Geenen; Arno van Rooij; Giel Berden; Marleen Cdg Huigen; Leo Aj Kluijtmans; Tessa Ma Peters; Hilal H Al-Shekaili; Blair R Leavitt; Erik de Vrieze; Sanne Broekman; Erwin van Wijk; Laura A Tseng; Purva Kulkarni; Floris Pjt Rutjes; Jasmin Mecinović; Eduard A Struys; Laura A Jansen; Sidney M Gospe; Saadet Mercimek-Andrews; Keith Hyland; Michèl Aap Willemsen; Levinus A Bok; Clara Dm van Karnebeek; Ron A Wevers; Thomas J Boltje; Jos Oomens; Jonathan Martens; Karlien Lm Coene
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 14.808

8.  Lysine-Restricted Diet as Adjunct Therapy for Pyridoxine-Dependent Epilepsy: The PDE Consortium Consensus Recommendations.

Authors:  Clara D M van Karnebeek; Sylvia Stockler-Ipsiroglu; Sravan Jaggumantri; Birgit Assmann; Peter Baxter; Daniela Buhas; Levinus A Bok; Barbara Cheng; Curtis R Coughlin; Anibh M Das; Alette Giezen; Wahla Al-Hertani; Gloria Ho; Uta Meyer; Philippa Mills; Barbara Plecko; Eduard Struys; Keiko Ueda; Monique Albersen; Nanda Verhoeven; Sidney M Gospe; Renata C Gallagher; Johan K L Van Hove; Hans Hartmann
Journal:  JIMD Rep       Date:  2014-04-19

Review 9.  The genotypic spectrum of ALDH7A1 mutations resulting in pyridoxine dependent epilepsy: A common epileptic encephalopathy.

Authors:  Curtis R Coughlin; Michael A Swanson; Elaine Spector; Naomi J L Meeks; Kathryn E Kronquist; Mezhgan Aslamy; Michael F Wempe; Clara D M van Karnebeek; Sidney M Gospe; Verena G Aziz; Becky P Tsai; Hanlin Gao; Peter L Nagy; Keith Hyland; Silvy J M van Dooren; Gajja S Salomons; Johan L K Van Hove
Journal:  J Inherit Metab Dis       Date:  2019-02-22       Impact factor: 4.982

Review 10.  Epileptic Encephalopathy in Childhood: A Stepwise Approach for Identification of Underlying Genetic Causes.

Authors:  Jaina Patel; Saadet Mercimek-Mahmutoglu
Journal:  Indian J Pediatr       Date:  2016-01-29       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.